PMID: 8225530Nov 1, 1993Paper

Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors

H BraschP Dominiak


Norepinephrine stores in electrically driven guinea pig isolated atria were loaded with [3H]norepinephrine, and norepinephrine release was deduced from the radioactivity efflux. Electrical field stimulation of sympathetic nerve endings was applied during the refractory period of atrial contractions. The stimulation-induced release of norepinephrine was increased by angiotensin II (Ang II) (10(-8) to 10(-6) mol/L) in a concentration-dependent manner. The maximum observed effect was a 55% augmentation. The effects of 10(-7) and 10(-6) mol/L Ang II were abolished by 10(-6) and 10(-5) mol/L of the subtype 1 Ang II receptor antagonist losartan, respectively. Losartan by itself (10(-6) mol/L) caused a 14% reduction of norepinephrine release. The subtype 2 Ang II receptor ligand PD 123319 (1-[[4-(dimethylamino)-3-methylphenyl]methyl]-5-(diphenylacetyl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid ditrifluoroacetate) in a concentration of 10(-4) mol/L had no detectable influence on transmitter release and did not antagonize the effect of Ang II. Angiotensin I (10(-6) and 10(-5) mol/L) increased norepinephrine release maximally by 23%. This effect was antagonized by 10(-5) mol/L losartan and did not appear in the pres...Continue Reading


Apr 1, 1977·Physiological Reviews·M J Peach
Jul 1, 1991·Naunyn-Schmiedeberg's Archives of Pharmacology·T K Keeton, A M Biediger
Mar 1, 1990·The American Journal of Physiology·J F Aceto, K M Baker
Sep 1, 1991·Naunyn-Schmiedeberg's Archives of Pharmacology·G RichardtA Schömig
Jan 1, 1986·Journal of Cardiovascular Pharmacology·W LinzY F Han
Jan 1, 1989·Clinical and Experimental Hypertension. Part A, Theory and Practice·W LinzD Ganten
Nov 30, 1989·Biochemical and Biophysical Research Communications·A T ChiuA L Johnson
Dec 1, 1989·Clinical and Experimental Pharmacology & Physiology·M A MianM J Rand
Aug 30, 1989·Biochemical and Biophysical Research Communications·S WhitebreadM de Gasparo
Jul 1, 1989·Naunyn-Schmiedeberg's Archives of Pharmacology·E BadoerT Unger
Jan 1, 1986·The American Journal of Physiology·M NakamaruT Inagami
Apr 24, 1987·The American Journal of Cardiology·W J GilchristS G Ball
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·P DominiakD Türck
Dec 1, 1966·The American Journal of Physiology·J A KrasneyW B Youmans
Jul 16, 1982·European Journal of Pharmacology·A NakashimaC I Johnston
Sep 1, 1981·Journal of Molecular and Cellular Cardiology·R S Kass, M L Blair
Sep 1, 1959·Klinische Wochenschrift·G KUSCHINSKY, H LUELLMANN

❮ Previous
Next ❯


Nov 15, 2011·Naunyn-Schmiedeberg's Archives of Pharmacology·Craig Comiter
Sep 24, 2008·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·Zengzhang LiuYuehui Yin
Jun 5, 2003·European Journal of Pharmacology·Alexander NapPieter A van Zwieten
Apr 8, 1999·Journal of the American College of Cardiology·H P Brunner-La RoccaM D Esler
Mar 1, 2011·Cardiovascular Research·Katrin WittköpperAli El-Armouche
May 11, 2001·Journal of Cardiovascular Pharmacology·R R WenzelT Philipp
Jul 11, 2001·Journal of Cardiovascular Pharmacology·M GrimmG Richardt
Jan 13, 2004·Journal of Cardiovascular Pharmacology·Malek El MuayedLars Christian Rump
Dec 1, 2007·Journal of Cardiovascular Pharmacology·R M A van de WalA A Voors
Sep 16, 2008·Journal of Cardiovascular Pharmacology·Dobromir Dobrev, Stanley Nattel
Aug 2, 2008·Journal of Cardiovascular Pharmacology·Tetsumasa SasaokaYasuo Matsumura
Sep 3, 2010·Journal of Hypertension·Laiyuan WangUNKNOWN GenSalt Collaborative Research Group
Oct 7, 1997·Clinical and Experimental Pharmacology & Physiology·H YokoyamaH Fujiwara
Dec 1, 2004·Kidney International·Hugh E de WardenerGraham A MacGregor
Oct 7, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Mirnela BykuThomas C Westfall
Mar 1, 1995·The Journal of Clinical Investigation·M LoJ Sassard
Jul 16, 2005·Advances in Therapy·Jacques de Champlain
Aug 27, 2002·Journal of Hypertension·Alexander NapPieter A Van Zwieten
Mar 17, 2009·The Journal of Sexual Medicine·Li-Ming Jin
May 15, 2007·Immunological Reviews·Alicia C ReidRoberto Levi
Jan 30, 2007·The Annals of Thoracic Surgery·Niyazi GulerHasan Ali Gumrukcuoglu
Feb 17, 2000·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Y TakataH Kato
Jun 8, 2015·Annales de cardiologie et d'angéiologie·J BohlenderH Imboden

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.